LONDON and DUBAI, UAE,
July 18,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative
diagnostics company focused on the detection of immune responses
and diagnosis of viral diseases, announced today that it has signed
contracts to launch two new research and laboratory facilities in
the United Kingdom.
The Company has signed a contract to launch a laboratory
facility at Scale Space. Scale Space is conveniently located in a
major metropolitan hub in the heart of the unique innovation
ecosystem at Imperial College London, a 23-acre research and
innovation district in White City, west London. The
state-of-the-art facility includes phlebotomy stations,
laboratories and research facilities, and offers access to
cutting-edge resources and networking opportunities, acting as a
catalyst for transforming ground-breaking ideas into practical
applications, and empowering organizations to make a lasting impact
on society.
If granted approval by the regulatory agencies, the site would
be instrumental in the initial launch of ViraxImmune™, acting as
the first laboratory for blood draw and analysis. The laboratory
would also give the Company the ability to fulfill third party
laboratory orders.
"This represents an important milestone in our mission to
provide a personalized and preventative healthcare solution that is
accurate, affordable and convenient," said James Foster,
Virax's Chairman of the Board of Directors and Chief Executive
Officer. "The UK-based laboratory provides us a scalable
infrastructure while avoiding the requirement for complex processes
and expensive lab equipment."
"This partnership marks an exciting achievement for Scale Space
as we work to foster innovation within the life science industry,"
said Michael Holmes, CEO of Scale
Space, "By welcoming Virax into our ecosystem, we aim to create an
even stronger community of forward-thinking industry leaders. With
Virax's exceptional expertise and vision, we are confident that our
collective impact will be amplified, propelling the global
population towards a new frontier of preventative healthcare."
Additionally, Virax has signed a lease agreement with BioCity
Glasgow to establish a research laboratory in Glasgow, United Kingdom.
The state-of-the-art facility is within proximity to top-ranked
institutions including the Universities of Glasgow and Edinburgh, and major hospitals and clinics in
Scotland. This convenient location
facilitates close cooperation with the National Health Service,
access to fresh blood samples and blood banks for ongoing and
future assessments, and collaborations with local research groups
specialized in immunology. As part of BioCity, the Company will
have access to cost-effective community facilities, and more
broadly, access to a number of additional communities of experts
based in incubators across the UK Science Parks Association and the
United Kingdom.
"Establishment of a facility in Glasgow extends our research capacity,
enabling us to simultaneously and independently develop multiple
new products within our ViraxImmune™ platform from early to late
stage, including verification and validation," James Foster, Virax's Chairman of the Board of
Directors and Chief Executive Officer.
"We are delighted to welcome Virax Biolabs to our growing life
science innovation ecosystem at BioCity Glasgow and our Pioneer
community of UK Science Parks Campuses," said John Mackenzie, Director (Scotland), The Pioneer Group. "Pioneer is
dedicated to helping young companies succeed in delivering
life-changing health solutions that will shape our future. We
believe in the mission driving Virax's business and have no doubt
that Virax's technology will strengthen our global approach to
immune health."
About Virax Biolabs Group Limited.
Founded in 2013, Virax Biolabs Group Limited is an innovative
biotech company focused on the detection of immune responses to and
diagnosis of viral diseases. In addition to distributing an array
of in-vitro diagnostic test kits, Virax Biolabs Group Limited is
currently developing a proprietary T-Cell Test technology with the
intention of providing an immunology profiling platform that
assesses each individual's immune risk profile against major global
viral threats. T-Cell testing can be particularly effective in the
diagnosis and therapeutics of COVID-19 as well as other threats
including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March 31, 2022.
Although we believe the expectations reflected in such
forward-looking statements are reasonable, we can give no assurance
that such expectations will prove to be correct. We are not
obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-continues-growth-and-expansion-with-the-addition-of-research-and-laboratory-facilities-301879125.html
SOURCE Virax Biolabs